MAXCYTE INC

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)


· · Three Months Ended June 30, · · · Six Months Ended June 30,
· 2024 · 2023 · · 2024 · 2023
Revenue	$10,429	$9,043	$21,770	$17,619
Cost of goods sold	1,488	1,376	2,891	2,376
Gross profit	8,941	7,667	18,879	15,243

Operating expenses:
Research and development	5,619	5,664	12,297	11,711
Sales and marketing	6,617	6,436	13,981	12,732
General and administrative	7,639	7,663	14,742	15,161
Depreciation and amortization	1,034	977	2,102	1,890
Total operating expenses	20,909	20,740	43,122	41,494
Operating loss	(11,968)	(13,073)	(24,243)	(26,251)

Other income:
Interest income	2,593	2,561	5,342	4,857
Total other income	2,593	2,561	5,342	4,857
Loss before income taxes	(9,375)	(10,512)	(18,901)	(21,394)
Provision for income taxes	—	—	—	—
Net loss	$(9,375)	$(10,512)	$(18,901)	$(21,394)
Basic and diluted net loss per share	$(0.09)	$(0.10)	$(0.18)	$(0.21)
Weighted average shares outstanding, basic and diluted	104,639,239	103,063,606	104,364,498	102,955,422

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.